BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America 2011;40:111-34. [DOI: 10.1016/j.ecl.2010.12.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15 [PMID: 28396845 DOI: 10.5662/wjm.v7.i1.9] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
2 Sun J. Pancreatic neuroendocrine tumors. Intractable Rare Dis Res 2017;6:21-8. [PMID: 28357177 DOI: 10.5582/irdr.2017.01007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
3 Halfdanarson TR, Howe JR, Haraldsdottir S, O'dorisio TM. Circulating tumor markers in patients with neuroendocrine tumors – a clinical perspective. International Journal of Endocrine Oncology 2015;2:89-99. [DOI: 10.2217/ije.14.38] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Dima SO, Dumitrascu T, Pechianu C, Grigorie RT, Brasoveanu V, Sorop A, Lupescu I, Purnichescu-Purtan R, Croitoru A, Bacalbasa N, Tanase A, Tomescu DR, Herlea V, Popescu I. PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS. Acta Endocrinol (Buchar) 2018;14:389-93. [PMID: 31149288 DOI: 10.4183/aeb.2018.389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Savelli G, Muni A, Falchi R, Zaniboni A, Barbieri R, Valmadre G, Minari C, Casi C, Rossini P. Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients. Ann Transl Med 2015;3:145. [PMID: 26207238 DOI: 10.3978/j.issn.2305-5839.2015.06.10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Appetecchia M, Lauretta R, Rota F, Carlini M. Neuroendocrine Tumors Biomarkers. In: Carlini M, editor. Abdominal Neuroendocrine Tumors. Milano: Springer Milan; 2018. pp. 65-78. [DOI: 10.1007/978-88-470-3955-1_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 2020;52:473-92. [PMID: 32234416 DOI: 10.1016/j.dld.2020.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
8 Herman Mahečić D, Cigrovski Berković M, Zjačić-Rotkvić V, Čačev T, Kapitanović S, Ulamec M. Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms. Bosn J Basic Med Sci 2020;20:445-50. [PMID: 32156252 DOI: 10.17305/bjbms.2020.4471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Dumlu EG, Karakoç D, Özdemir A. Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies. Int Surg 2015;100:1089-97. [PMID: 25590518 DOI: 10.9738/INTSURG-D-14-00204.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
10 Mateo J, Heymach JV, Zurita AJ. Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors: Current Data and Clinical Outlook. Mol Diagn Ther 2012;16:151-61. [DOI: 10.1007/bf03262203] [Cited by in Crossref: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Review of Gastroenterology & Hepatology 2014;6:313-34. [DOI: 10.1586/egh.12.15] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
12 Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. Journal of Surgical Research 2016;201:38-43. [DOI: 10.1016/j.jss.2015.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
13 Fottner C, Ferrata M, Weber MM. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017;18:393-410. [PMID: 29256148 DOI: 10.1007/s11154-017-9438-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
14 Strid H, Simrén M, Lasson A, Isaksson S, Stridsberg M, Öhman L. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. J Crohns Colitis 2013;7:e615-22. [PMID: 23694857 DOI: 10.1016/j.crohns.2013.04.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
15 Sommer WH, Ceelen F, García-albéniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol 2013;23:3094-103. [DOI: 10.1007/s00330-013-2925-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
16 Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meeran KM, Chapman RS, Caplin M, Ghatei MA, Bloom SR, Martin NM. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol (Oxf) 2012;76:831-6. [PMID: 22175276 DOI: 10.1111/j.1365-2265.2011.04319.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
17 Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi MG, Giampietro A, Rufini V, Inzani F, Giordano A, Rindi G, Pontecorvi A, De Marinis L. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study. Endocrine 2018;60:362-7. [PMID: 28567607 DOI: 10.1007/s12020-017-1327-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Alshabi AM, Vastrad B, Shaikh IA, Vastrad C. Identification of important invasion and proliferation related genes in adrenocortical carcinoma. Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1296-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect 2019;8:625-33. [PMID: 30999279 DOI: 10.1530/EC-19-0068] [Reference Citation Analysis]
20 Jang S, Janssen A, Aburjania Z, Robers MB, Harrison A, Dammalapati A, Cheng YQ, Chen H, Jaskula-Sztul R. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. Oncotarget 2017;8:70828-40. [PMID: 29050323 DOI: 10.18632/oncotarget.19993] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
21 Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20:187-196. [PMID: 23319495 DOI: 10.1530/erc-12-0340] [Cited by in Crossref: 65] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
22 Guarneri G, Gasparini G, Crippa S, Andreasi V, Falconi M. Diagnostic strategy with a solid pancreatic mass. La Presse Médicale 2019;48:e125-45. [DOI: 10.1016/j.lpm.2019.02.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
23 Kim MK, Warner RR, Ward SC, Harpaz N, Roayaie S, Schwartz ME, Itzkowitz S, Wisnivesky J. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology 2015;101:58-65. [PMID: 25572143 DOI: 10.1159/000371807] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
24 Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs 2013;24:66-72. [PMID: 23147412 DOI: 10.1097/CAD.0b013e3283584f75] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
25 Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21:612-618. [PMID: 30366884 DOI: 10.1016/j.hpb.2018.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
26 Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22:561-575. [PMID: 26037279 DOI: 10.1530/erc-15-0092] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
27 Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016;22:1011-1017. [PMID: 26482044 DOI: 10.1158/1078-0432.ccr-15-0548] [Cited by in Crossref: 155] [Cited by in F6Publishing: 81] [Article Influence: 22.1] [Reference Citation Analysis]
28 Kruljac I, Vurnek I, Maasberg S, Kust D, Blaslov K, Ladika Davidović B, Štefanović M, Demirović A, Bišćanin A, Filipović-čugura J, Marić Brozić J, Pape U, Vrkljan M. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms. Endocrine 2018;60:395-406. [DOI: 10.1007/s12020-018-1592-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Göke B, Auernhammer CJ. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 2012;4:141-55. [PMID: 24213232 DOI: 10.3390/cancers4010141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
30 Langer SW, Ringholm L, Dali CI, Petersen RH, Rasmussen ÅK, Gerdes AM, Federspiel B, Knigge UP. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases. Case Rep Med 2015;2015:265786. [PMID: 26798346 DOI: 10.1155/2015/265786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin MS, Sundaram C, Puligopu AK, Ankathi P, Purohit AK, Chandak GR, Harsha HC, Sirdeshmukh R. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One 2012;7:e46153. [PMID: 23029420 DOI: 10.1371/journal.pone.0046153] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
32 Sepúlveda-Méndez J, de Murphy CA, Pedraza-López M, Murphy-Stack E, Rojas-Bautista JC, González-Treviño O. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun 2012;33:69-79. [PMID: 21970835 DOI: 10.1097/MNM.0b013e32834cecfe] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mateo J, Heymach JV, Zurita AJ. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther 2012;16:151-61. [PMID: 22515658 DOI: 10.2165/11632590-000000000-00000] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
34 Bílek R, Zelinka T, Vlček P, Dušková J, Michalský D, Novák K, Václavíková E, Widimský J Jr. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiol Res 2017;66:S397-408. [PMID: 28948824 DOI: 10.33549/physiolres.933719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology 2017;113:268-82. [DOI: 10.1016/j.critrevonc.2017.03.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
36 Onal IK, Ibis M, Arhan M. Chromogranin A as a marker of disease activity in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2014;49:1501-2. [DOI: 10.3109/00365521.2014.953573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Zhang H, Shen G, Zhang S, Du F, Cao Y, Jiang J, Zheng F, Ma X, Wang Z, Ren D, Ahmad R, Zhao F, Zhao J. Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update. Expert Opin Pharmacother 2018;19:795-807. [PMID: 29693454 DOI: 10.1080/14656566.2018.1465928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Zanini S, Giovinazzo F, Alaimo D, Lawrence B, Pfragner R, Bassi C, Modlin I, Kidd M. GNA15 expression in small intestinal neuroendocrine neoplasia: Functional and signalling pathway analyses. Cellular Signalling 2015;27:899-907. [DOI: 10.1016/j.cellsig.2015.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
39 Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. J Gastrointest Cancer 2016;47:366-74. [PMID: 27619395 DOI: 10.1007/s12029-016-9866-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 García-Carbonero R, Vilardell F, Jiménez-Fonseca P, González-Campora R, González E, Cuatrecasas M, Capdevila J, Aranda I, Barriuso J, Matías-Guiu X; Spanish Society of Pathology., Spanish Society of Medical Oncology. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2014;16:243-56. [PMID: 23749327 DOI: 10.1007/s12094-013-1062-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
41 Kavecansky J, Wei L, Caronia L, Ramirez MT, Bloomston M, Shah MH. Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center. Pancreas 2015;44:198-203. [PMID: 25411805 DOI: 10.1097/MPA.0000000000000267] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
42 Luo X, He JY, Xu J, Hu SY, Mo BH, Shu QX, Chen C, Gong YZ, Zhao XL, Xie GF, Yu ST. Vascular NRP2 triggers PNET angiogenesis by activating the SSH1-cofilin axis. Cell Biosci 2020;10:113. [PMID: 32983407 DOI: 10.1186/s13578-020-00472-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Plenis A, Miękus N, Olędzka I, Bączek T, Lewczuk A, Woźniak Z, Koszałka P, Seroczyńska B, Skokowski J. Chemometric evaluation of urinary steroid hormone levels as potential biomarkers of neuroendocrine tumors. Molecules 2013;18:12857-76. [PMID: 24135941 DOI: 10.3390/molecules181012857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Ro C, Chai W, Yu VE, Yu R. Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chin J Cancer. 2013;32:312-324. [PMID: 23237225 DOI: 10.5732/cjc.012.10295] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
45 Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes 2016;23:28-37. [PMID: 26627724 DOI: 10.1097/MED.0000000000000215] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
46 Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E, Gryczyńska M, Ruchała M. Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 2016;12:1-9. [PMID: 26925113 DOI: 10.5114/aoms.2016.57577] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
47 Kulkarni HR, Baum RP. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin 2014;9:91-7. [PMID: 25029938 DOI: 10.1016/j.cpet.2013.08.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
48 Xu X, Honda K, Miura N, Hori S, Le Blanc S, Bergmann F, Gaida MM, Volkmar M, Schimmack S, Hackert T, Strobel O, Felix K. Actinin-4 splice variant - a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplasms. J Cancer 2020;11:2318-28. [PMID: 32127958 DOI: 10.7150/jca.37503] [Reference Citation Analysis]
49 Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf) 2016;85:400-7. [PMID: 27256431 DOI: 10.1111/cen.13119] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
50 Cheng Y, Sun Z, Bai C, Yan X, Qin R, Meng C, Ying H. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors. Tumor Biol 2016;37:2863-9. [DOI: 10.1007/s13277-015-4114-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 d'Herbomez M, Bauters C, Cortet-Rudelli C, Dewailly D, Docao C, Wémeau JL. [Biomarkers in endocrinology]. Presse Med 2014;43:40-56. [PMID: 24342177 DOI: 10.1016/j.lpm.2013.11.003] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Modlin IM, Drozdov I, Bodei L, Kidd M. Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMC Cancer 2014;14:564. [PMID: 25095873 DOI: 10.1186/1471-2407-14-564] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
54 Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21:615-628. [PMID: 25015994 DOI: 10.1530/erc-14-0190] [Cited by in Crossref: 63] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
55 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
56 Vinik AI, Chaya C. Clinical Presentation and Diagnosis of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30:21-48. [PMID: 26614367 DOI: 10.1016/j.hoc.2015.08.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
57 Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015;110:1223-1232. [PMID: 26032155 DOI: 10.1038/ajg.2015.160] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
58 Palepu J, Shrikhande SV, Bhaduri D, Shah RC, Sirohi B, Chhabra V, Dhar P, Sastry R, Sikora S. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry. Indian J Gastroenterol 2017;36:445-51. [DOI: 10.1007/s12664-017-0808-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J Jr, Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019;11:E586. [PMID: 31027285 DOI: 10.3390/cancers11040586] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
60 Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30:59-77. [PMID: 26971844 DOI: 10.1016/j.beem.2016.01.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
61 Lewis MA, Thompson GB, Young WF Jr. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg 2012;36:1375-81. [PMID: 22382771 DOI: 10.1007/s00268-012-1539-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
62 Modlin IM, Drozdov I, Kidd M. Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clinical Chemistry and Laboratory Medicine (CCLM) 2014;52:419-29. [DOI: 10.1515/cclm-2013-0496] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
63 Linecker M, Kambakamba P, Raptis DA, Malagó M, Ratti F, Aldrighetti L, Robles-Campos R, Lehwald-Tywuschik N, Knoefel WT, Balci D, Ardiles V, De Santibañes E, Truant S, Pruvot FR, Stavrou GA, Oldhafer KJ, Voskanyan S, Mahadevappa B, Kozyrin I, Low JK, Ferrri V, Vicente E, Prachalias A, Pizanias M, Clift AK, Petrowsky H, Clavien PA, Frilling A. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. HPB (Oxford) 2020;22:537-44. [PMID: 31540885 DOI: 10.1016/j.hpb.2019.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
64 Noor M, Huber AR, Cates JMM, Gonzalez RS. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation. Histopathology 2021;79:416-26. [PMID: 33754384 DOI: 10.1111/his.14369] [Reference Citation Analysis]
65 Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238-1246. [PMID: 25808630 DOI: 10.1007/s00259-015-3041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR. Quantifying the Effects of Renal Impairment on Plasma Concentrations of the Neuroendocrine Neoplasia Biomarkers Chromogranin A, Chromogranin B, and Cocaine- and Amphetamine-Regulated Transcript. Clinical Chemistry 2012;58:941-3. [DOI: 10.1373/clinchem.2011.176099] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
67 Pusceddu S, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M, Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology 2015;11:1947-59. [DOI: 10.2217/fon.15.86] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
68 de Mestier L, Dromain C, d'Assignies G, Scoazec J, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocrine-Related Cancer 2014;21:R105-20. [DOI: 10.1530/erc-13-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
69 Papalou O, Peppa M, Kandaraki E, Diamanti-kandarakis E, Nikou G. The Diagnostic Value of Chromogranin A in Neuroendocrine Neoplasms is Potentiated by Clinical Factors and Inflammatory Markers. Endocrines 2020;1:1-12. [DOI: 10.3390/endocrines1010001] [Reference Citation Analysis]
70 Tseng CM, Cheng TY, Chen TB, Tien YW, Chen CC, Lin JT, Wang HP. Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol Lett 2018;15:8951-8. [PMID: 29805630 DOI: 10.3892/ol.2018.8472] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine tumors. Indian J Gastroenterol 2013;32:3-17. [PMID: 23054950 DOI: 10.1007/s12664-012-0257-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Basuroy R, Sarker D, Quaglia A, Srirajaskanthan R, Ramage J. Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream? International Journal of Endocrine Oncology 2015;2:201-15. [DOI: 10.2217/ije.15.9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 8.2] [Reference Citation Analysis]
74 Zatelli MC, Fanciulli G, Malandrino P, Ramundo V, Faggiano A, Colao A; NIKE Group. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. Endocr Relat Cancer 2016;23:R173-83. [PMID: 26666705 DOI: 10.1530/ERC-15-0413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
75 de Mestier L, Deguelte-lardière S, Brixi H, Kianmanesh R, Cadiot G. Tumeurs neuroendocrines digestives. La Revue de Médecine Interne 2016;37:551-60. [DOI: 10.1016/j.revmed.2016.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
76 Wang Y, Huang K, Chen J, Luo Y, Zhang Y, Jia Y, Xu L, Chen M, Huang B, Ni D, Li ZP, Feng ST. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. Contrast Media Mol Imaging 2018;2018:6037273. [PMID: 30510495 DOI: 10.1155/2018/6037273] [Reference Citation Analysis]
77 Kuriry H, Swied AM. Large-Cell Neuroendocrine Carcinoma of the Esophagus: A Case from Saudi Arabia. Case Rep Gastroenterol. 2015;9:327-334. [PMID: 26600769 DOI: 10.1159/000441381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
78 Frilling A, Akerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19:R163-R185. [PMID: 22645227 DOI: 10.1530/erc-12-0024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
79 Yu R, Wachsman A. Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls. Endocrinol Metab Clin North Am 2017;46:795-814. [PMID: 28760239 DOI: 10.1016/j.ecl.2017.04.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
80 Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, Caplin ME, Toumpanakis C. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3:118. [PMID: 26207246 DOI: 10.3978/j.issn.2305-5839.2015.04.23] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
81 Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel) 2019;11:E1113. [PMID: 31382663 DOI: 10.3390/cancers11081113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
82 Malik P, Pinto C, Naparst MS, Ward SC, Aronson A, Aalberg JJ, Divino CM, Kim MK. Impact of Mesenteric Mass in Patients With Midgut Neuroendocrine Tumors. Pancreas 2019;48:682-5. [PMID: 31091215 DOI: 10.1097/MPA.0000000000001309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
83 Broedbaek K, Hilsted L. Chromogranin A as biomarker in diabetes. Biomark Med. 2016;10:1181-1189. [PMID: 27611656 DOI: 10.2217/bmm-2016-0091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
84 Paquette CE, Kent ML, Buchner C, Tanguay RL, Guillemin K, Mason TJ, Peterson TS. A retrospective study of the prevalence and classification of intestinal neoplasia in zebrafish (Danio rerio). Zebrafish 2013;10:228-36. [PMID: 23544991 DOI: 10.1089/zeb.2012.0828] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
85 Robbins HL, Symington M, Mosterman B, Tranter F, Davies L, Randeva HS, Penedo A, Ferreira C, Darby C, Grammatopoulos D, Kaltsas G, Weickert MO. Effects of intake of breakfast or caffeine-containing beverages on measurement of circulating chromogranin A in plasma. GastroHep 2019;1:11-21. [DOI: 10.1002/ygh2.208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Basuroy R, Srirajaskanthan R, Ramage JK. Neuroendocrine Tumors. Gastroenterol Clin North Am 2016;45:487-507. [PMID: 27546845 DOI: 10.1016/j.gtc.2016.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
87 Sathe G, Albert M, Darrow J, Saito A, Troncoso J, Pandey A, Moghekar A. Quantitative proteomic analysis of the frontal cortex in Alzheimer's disease. J Neurochem 2021;156:988-1002. [PMID: 32614981 DOI: 10.1111/jnc.15116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
88 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
89 Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S. Non-functioning pancreatic neuroendocrine tumors: Surgery or observation? World J Gastrointest Endosc 2017; 9(4): 153-161 [PMID: 28465781 DOI: 10.4253/wjge.v9.i4.153] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
90 Díaz Pérez JÁ, Currás Freixes M. [Chromogranin A and neuroendocrine tumors]. Endocrinol Nutr 2013;60:386-95. [PMID: 23271036 DOI: 10.1016/j.endonu.2012.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
91 Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, Kaemmerer D, Hommann M, Hörsch D, Bonomo L. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging. 2012;37:1004-1020. [PMID: 22422069 DOI: 10.1007/s00261-012-9871-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
92 Aluri V, Dillon JS. Biochemical Testing in Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2017;46:669-77. [PMID: 28760232 DOI: 10.1016/j.ecl.2017.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
93 Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
94 Danda R, Ganapathy K, Sathe G, Madugundu AK, Ramachandran S, Krishnan UM, Khetan V, Rishi P, Keshava Prasad TS, Pandey A, Krishnakumar S, Gowda H, Elchuri SV. Proteomic profiling of retinoblastoma by high resolution mass spectrometry. Clin Proteomics 2016;13:29. [PMID: 27799869 DOI: 10.1186/s12014-016-9128-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
95 Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, Chung KM. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2018;47:485-504. [PMID: 30098712 DOI: 10.1016/j.ecl.2018.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
96 Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64. [PMID: 25099181 DOI: 10.1186/1472-6823-14-64] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]